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Abstract 
The unique geographic isolation of Australia has resulted in the evolution of a distinctive range 
of Australian arachnid fauna. Through the pioneering work of a number of Australian arachnologists, 
toxinologists and clinicians, the taxonomy and distribution of new species, the effective clinical 
treatment of envenomation, and the isolation and characterisation of the many distinctive neurotoxins, 
has been achieved. In particular, work has focused on several Australian arachnids, including red-back 
and funnel-web spiders, paralysis ticks and buthid scorpions that contain neurotoxins capable of 
causing death or serious systemic envenomation. In the case of spiders, species-specific antivenoms 
have been developed to treat envenomed patients that show considerable cross-reactivity. Both in vitro 
and clinical case studies have shown they are particularly efficacious in the treatment of envenomation 
by spiders even from unrelated families. Despite their notorious reputation, the high selectivity and 
potency of a unique range of toxins from the venom of Australian arachnids will make them invaluable 
molecular tools for studies of neurotransmitter release and vesicle exocytosis as well as ion channel 
structure and function. The venoms of funnel-web spiders, and more recently Australian scorpions, 
have also provided a previously untapped rich source of insect-selective neurotoxins for the future 
development of biopesticides and the characterisation of previously unvalidated insecticide targets. 
This review provides an historical viewpoint of the work of many toxinologists to isolate and 
characterise just some of the toxins produced by such a unique group of arachnids and examines the 
potential applications of these novel peptides.  
 
Keywords: Australian spiders, α-Latrotoxin, Atracotoxins, Missulenatoxins, Australian scorpions, 
Australian paralysis tick, Antivenom, bioinsecticide 
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Abbreviations: Aah-II, mammalian-selective scorpion α-toxin isolated from the venom of Androctonus 
australis hector; ACTX, atracotoxin isolated from spiders belonging to the sub-family Atracinae 
(Australian Funnel-web spiders - Hadronyche and Atrax species); δ-ACTX, voltage-gated Na channel 
specific atracotoxins, κ-ACTX, insect-selective calcium-activated potassium channel blocking 
atracotoxins (formerly known as J-ACTX); ω-ACTX, insect-selective voltage-gated Ca channel 
blocking atracotoxin; µ-Aga, µ-agatoxin from the American funnel-web spider Agelenopsis aperta; 
BKCa, large conductance calcium-activated potassium channel; Bv8, protein Bv8 from the yellow-
bellied toad Bombina variegata; CIRL, calcium-independent receptor for latrotoxin (also known as 
latrophilin 1); Cls, CIRL and latrophilin receptors; HPLC, high-performance liquid chromatography; 
hPK, human prokineticin; HT, holocyclotoxin from the Australian paralysis tick Ixodes holocyclus; 
ICK, inhibitor cystine-knot; IgG, immunoglobulin G; IgM, immunoglobulin M; LD50, median lethal 
dose; α-LTx, vertebrate-selective latrotoxin from the venom of the European widow spider Latrodectus 
tredecimguttatus; LqhαIT, insect-selective scorpion α-insect toxin isolated form the venom of Leiurus 
quinquestriatus hebraeus; MIT1, mamba intestinal toxin 1 from the black mamba snake Dendroaspis 
p. polylepis; MSTX, missulenatoxin isolated from mouse spiders of the genus Missulena; δ-MSTX, 
voltage-gated sodium channel specific missulenatoxin; NMR, nuclear magnetic resonance; s.c., 
subcutaneous; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; TTX, 
tetrodotoxin; VGCC, voltage-gated calcium channel; VGSC, voltage-gated sodium channel. 
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Few, if any other groups of venomous animals conjure up the emotion of fear, the potential 
human medical risks, and the economic losses to companion and stock animals than members of the 
class Arachnida. Important venomous creatures in this class include the order Scorpionida (scorpions), 
order Araneae (spiders) and order Acarina (ticks) (Fig. 1A). Yet many of these creatures, particularly 
spiders and scorpions, present an immense combinatorial peptide library for the potential development 
of insecticides and pharmaceuticals which to date has gone largely untapped. Importantly, Australia 
represents a unique biological environment that supports distinctive species within these orders that 
continue to be the focus of toxinologists. 
Figure 1 here 
This review will concentrate primarily on Australian research investigating clinical features of 
envenomation and treatment, and the biochemistry and pharmacology of venoms from classes Araneae 
and Acarina. Despite the lack of mammalian activity of most species of Australian scorpions, and 
hence limited investigation, a cursory coverage is provided for completeness. Included in the review is 
the work of Australian researchers investigating the commercial application of these neurotoxins in the 
fields of pharmacology and neuroscience and the development of novel insecticides for the control of 
phytophagous pests and insect vectors of disease.  
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2. Australian spider toxinology 
Apart from insects, spiders represent one of the most successful terrestrial invertebrates with 
over 38,000 described species worldwide (Platnick, 1997). Spider venoms contain potent neurotoxins 
and other bioactive compounds, many of which are lethal to humans or selectively insecticidal. Many 
of these neurotoxins are highly potent and specifically target ion channels, receptors or other targets 
involved in important physiological functions (for extensive reviews of spider toxin structure and 
function see Escoubas et al., 2000; Nicholson and Graudins, 2002; Rash and Hodgson, 2002). Others 
are now being investigated for their possible use as bioinsecticidal agents for the control of 
insecticide-resistant pests (for reviews see King et al., 2002; Maggio et al., 2004; Tedford et al., 2004).  
In Australia, spiders are the most widely distributed venomous creatures with a conservative 
estimate of over 10,000 species in this country (Raven, 1988). However, there is a distinct lack of 
knowledge of the distribution and venom composition of the vast majority of these spiders. The most 
notable exceptions are the red-back (Latrodectus hasselti), funnel-web (Atrax and Hadronyche spp.) 
and to a lesser extent mouse spiders (Missulena spp.) and cupboard spiders (Steatoda spp.) (Fig. 
2A-D). These contain potentially lethal primate and insecticidal neurotoxins and have become the focus 
of Australian spider toxinology research since the pioneering studies of Charles Kellaway, Alan 
Musgrave and Saul Weiner. 
Figure 2 here 
 
2.1. Australian spider envenomation: extent of the problem 
The true incidence of spider bite, systemic envenomation and death resulting from spider bite in 
humans world-wide is unknown due the paucity of data from poisoning and envenomation cases in 
most regions, particularly definite bites from identified species. Nevertheless, in Australia there are 
about 4000-5000 calls each year for information about spider bites to the New South Wales Poisons 
Information Centre, the largest centre in the country. This is only eclipsed by paracetamol as the most 
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frequent reason for inquiries (Kirby, 1998; Duggin et al., 2002). Unfortunately, data collection on the 
calls is extremely limited and the true incidence of spider bite in the general community is more than 
likely under-represented by these figures. Although most cases of spider bite result in minimal, if any, 
significant clinical consequences, in Australia there are a number of spider neurotoxins that may 
produce either serious systemic clinical envenomation syndromes or significant local reactions. The 
extent of this problem has been recently addressed by Geoff Isbister (Newcastle Mater Misericordiae 
Hospital, Newcastle) and Mike Gray (Australian Museum, Sydney) where a prospective study has 
investigated the types of spiders involved in envenomations in Australia, and the severity of any 
clinical effects (Isbister and Gray, 2002). 
 
2.2. Widow spiders: genus Latrodectus 
2.2.1. Taxonomy and distribution 
Arguably the most clinically significant group of spiders worldwide and specifically in 
Australia are the widow or comb-footed spiders (Araneae: Araneomorphae: Theridiidae), mainly 
belonging to the genus Latrodectus. In Australia, medically important theridiid spiders are from three 
genera. These include the red-back spider (Latrodectus hasselti; Fig. 2A), cupboard spiders (Steatoda 
capensis and S. grossa; Fig. 2B) and to a much lesser extent Archaearaneae spp. Despite their 
potentially fatal bite, as is the case with the red-back spider, little is known about the true incidence of 
envenomation from theridiid spiders due to a lack of organised data collection in most regions of the 
world. In Australia, a gross estimate of over 5000 L. hasselti bites per year has been made (Isbister and 
White, 2004). Nevertheless, there is considerable geographic variation in the incidence of bites with far 
more in the temperate regions of Australia, particularly New South Wales, and far fewer in the colder 
south or tropical north (Sutherland and Trinca, 1978; Woo and Smart, 1999; Isbister et al., 2001; 
Isbister and Gray, 2002).  
Figure 3 here 
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Interestingly, Australian clinicians and scientists in the 1920’s originally disagreed as to 
whether or not L. hasselti was to be considered dangerous. Several studies by the early Australian 
toxinologist Musgrave and others confirmed that L. hasselti bites were potentially lethal (Jackson, 
1927; Cleland, 1932; Ingram and Musgrave, 1933). Indeed, clinically significant red-back spider 
envenomation requiring antivenom therapy occurs in around 20% of cases (White, 1998). While the 
antivenom is very effective, latrodectism should still be regarded as potentially fatal with the most 
recent death attributable to L. hasselti occurring as recently as 1999 (as reported by Sutherland and 
Tibballs, 2001d). Although rarely fatal, envenomation by Latrodectus spp. may result in an 
incapacitating syndrome of severe local, regional, or systemic pain and autonomic features called 
‘latrodectism’ which, if left untreated, may last for several days or weeks. Notwithstanding the 
frequency of bites by Australian red-back spiders there are only a few studies that clearly describe the 
clinical effects of L. hasselti (reviewed in Isbister and White, 2004).  
 
2.2.2. Latrodectism: clinical features of Latrodectus envenomation 
Specifically in Australia, clear clinical studies of the effects of the bite and effectiveness of 
antivenoms have been mainly carried out by four groups headed by Geoff Isbister (Newcastle Mater 
Misericordiae Hospital, Newcastle), Julian White (Women’s and Children’s Hospital, Adelaide) and 
George Jelinek (Sir Charles Gardiner Hospital, Perth) and Struan Sutherland (Commonwealth Serum 
Labratories, Melbourne). The syndrome of latrodectism may vary in severity depending on the species 
and size of the spider, the season, and the amount of venom injected but appears to be similar 
regardless of the geographic location of the spider (Maretic, 1983; Muller, 1993; Zukowski, 1993). 
Most commonly local pain, sweating, erythema, and piloerection are noted at the bite site within 1 
hour. Clinical features may remain isolated to the site of the bite or less commonly progress to become 
regional or systemic. Regional features may be heralded by the development of lymphangitis towards 
regional lymph nodes that may be palpable and painful. Other regional features may include those seen 
 G.M. Nicholson et al. 9 
at the bite site. Piloerection, sweating, and muscle fasciculation may be distributed throughout the 
bitten limb, in both limbs or in the contralateral limb only. The predominant feature of generalised 
latrodectism, however, is pain. Upper limb bites may result in pain predominantly to the face, neck, or 
chest, while bites to the lower limbs may produce abdominal and buttock pain (White et al., 1995). 
Patients may develop generalised diaphoresis, muscle pains, weakness, vomiting, tachycardia, 
hypertension, dyspnoea, and intermittent muscle twitching or tremor (Maretic, 1983; White et al., 
1995). When severe envenomation occurs death may result but typically only in young infants or the 
very elderly. The natural progression of envenomation is a gradual diminution of symptoms and signs 
over several days to weeks although, uncommonly, features of envenomation may persist for months. 
A recent prospective study of red-back spider bites in Australia showed that the majority of bites cause 
significant effects with severe and persistent pain occurring in two thirds of bites, sufficiently severe to 
prevent the patient sleeping in almost a third of all cases (Isbister and Gray, 2003c).  
 
2.2.3. Red-back spider venom 
Original studies of L. hasselti venom were undertaken by Wiener who assayed venom toxicity 
and developed an antivenom in rabbits (Drummond and Wiener, 1956; Wiener, 1956a; b). While 
extensive research has been carried out on the venom and toxins of overseas species of Latrodectus 
(over 400 papers), surprisingly little research has been undertaken on the venom of the Australian 
red-back spider. Nevertheless, the venoms of all Latrodectus spp. are thought to contain similar toxic 
components. This claim is based on three significant observations. Firstly, envenomation resulting from 
the bite of any widow spider results in a similar clinical picture regardless of the species of spider 
(section 2.2.2). Secondly, widow spider antivenoms produced using the venoms of specific Latrodectus 
spp. reverse the effects of envenomation from other Latrodectus spiders both in experimental animal 
models and in the clinical setting (section 2.2.5). Lastly, recent extensive but incomplete sequencing of 
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an α-latrotoxin from the red-back spider shows high homology with α-latrotoxin from the European 
widow spider (section 2.2.4). 
 
2.2.4. α-Latrotoxin: from function to structure 
There have been many reviews of the structure and mechanisms of actions of α-latrotoxin 
(α-LTx) the 120 kDa neurotoxin responsible for the clinical effects of widow spiders on nerve 
terminals (for reviews see Sudhof, 2001; Ushkaryov, 2002; Ushkaryov et al., 2004). Surprisingly, 
isolation and complete sequencing of the neurotoxin responsible for latrodectism has only been 
reported from the European widow spider L. tredecimguttatus and currently there are no published 
reports of identification of the neurotoxin from other overseas species. Nevertheless, the similar 
symptoms observed in clinical cases of red-back spider envenomation, together with cross-reactivity in 
Western blots using red-back antivenoms, and the prevention of toxicity by L. tredecimguttatus venom 
in mice studies all suggest that the neurotoxin is likely to be very similar (Daly et al., 2001; Graudins et 
al., 2001; Graudins et al., 2002a). Indeed, recent studies carried out by the authors indicate that, 
following partial sequencing of the gene encoding for α-latrotoxin from L. hasselti, there is 95% 
homology in amino acid sequence between latrotoxins from different species and similar mechanisms 
of neurotoxicity of L. hasselti neurotoxins (Graudins et al., 2002b).  
The overall action of α-LTx or crude Latrodectus spider venom is to cause massive synaptic 
vesicle exocytosis from the presynaptic terminal (Sudhof, 2001; Ushkaryov, 2002; Ushkaryov et al., 
2004). In brief, there appears to be four distinct steps: (a) α-LTx binds with high affinity to one or both 
of its receptors localised close to the active zone in the presynaptic plasma membrane. The first of these 
protein receptors are the neurexins, a calcium-dependent family of single transmembrane domain 
neuron-specific cell-adhesion molecules. The second class of α-LTx receptors are a 
calcium-independent receptor class called CLs (for CIRL and latrophilins) simultaneously described by 
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two groups; (b) after binding with either CLs or neurexins, the entire N-terminal portion of α-LTx then 
inserts into the presynaptic plasma membrane; (c) The toxin then forms divalent cation-dependent 
multimers in the membrane creating a nonselective cation channel, and (d) finally the toxin causes 
intracellular activation of exocytosis. In the final mechanism, α-LTx has a dual mechanism of action to 
trigger vesicle exocytosis. In one mode, α-LTx acts as a channel in the membrane that conducts 
calcium triggering a number of intracellular events as well as mediating release of neurotransmitter 
from the cytosol. In the second mode, α-LTx directly stimulates exocytosis of small clear vesicles in a 
calcium-independent manner. Eventually the action of α-LTx results in the depletion of synaptic 
vesicles, with vesicle endocytosis unable to compensate for the increased exocytosis. In summary, the 
current hypothesis is that α-LTx interferes with a process that normally inhibits vesicle fusion in the 
absence of calcium.  
 More recently the oligomerisation and three-dimensional structure of α-LTx has been 
determined. Initial reports identified that α-LTx, under normal conditions, exists as a dimer but can 
tetramerise in the presence of divalent cations or amphipathic molecules. Indeed it is now believed that 
the tetramer most likely represents the active form of α-LTx (Ashton et al., 2000). The three 
dimensional structure of the α-LTx monomer has been determined using cryo electron microscopy and 
found to consist of three main domains: a N-terminal wing connected to a large L-shaped body which, 
in turn, is attached to a C-terminal head region via a short thin neck forming a very angled molecule. 
The α-LTx tetramer complex consists of four monomers arranged in a four-bladed propeller formation 
surrounding a central pore with a minimum diameter of 10 Å. Therefore upon binding of the 
hydrophobic base of the tetramer to cell-surface receptors the central pore allows the passage of 
divalent, and certain monovalent, cations (Orlova et al., 2000) but also causes leakage of the transmitter 
pool that is present in the nerve terminal (Ashton et al., 2000; Ashton et al., 2001). Research into the 
precise mechanism of action is ongoing and is likely to result in a major advancement in our 
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understanding of the intracellular signaling transduction machinery, the biochemical differences and 
locations of the readily releasable and depot pools of synaptic vesicles, and how the release processes 
at various synapses differs. 
 
2.2.5. Treatment and management of latrodectism 
The availability of various spider antivenoms and their use has been recently reviewed (Isbister et 
al., 2003a; Nicholson and Graudins, 2003). It is commonly held that antivenom therapy is the most 
effective treatment for the symptoms and signs of latrodectism particularly in Australia where a 
species-specific antivenom is available (Wiener, 1956b; 1961b; Sutherland and Trinca, 1978; Clark et 
al., 1992). Patients receiving antivenom therapy are more likely to be discharged home directly from 
emergency departments and have much shorter hospital stays than those receiving supportive measures 
alone (Clark et al., 1992). Despite this there is some unwillingness to use widow spider antivenoms in 
some countries, particularly North America, because of a perceived high risk of allergic reactions to 
crotalid snake antivenoms (Dart and McNally, 2001) and a single fatal case following black widow 
antivenoms (Clark et al., 1992). Yet there is little likelihood of early allergic reactions with most 
widow spider antivenoms, based on studies in the United States and Australia (Sutherland and Trinca, 
1978; Clark, 2001). In Australia, a high percentage of red-back spider bites cause severe systemic 
effects (Sutherland and Trinca, 1978; Isbister and Gray, 2003c; Trethewy et al., 2003) such that 
antivenom is warranted in up to two thirds of these cases (Isbister and White, 2004). However, there is 
ongoing controversy as to the route of administration with increasing data indicating that the 
intramuscular route is far less useful than previously believed (Isbister, 2002; Isbister and Gray, 
2003c). This issue is currently being addressed by a randomised controlled trial conducted by Geoff 
Isbister.  
Specific antivenoms raised against the venoms of various Latrodectus spp. have been developed 
in many regions of the world. In Australia a species-specific antivenom was originally raised in rabbits 
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to the venom of the red-back spider (Wiener, 1956b), more recently the antivenom is now marketed as 
an equine F(ab’)2 fragment. This is the most commonly used antivenom in the country (Sutherland and 
Trinca, 1978; White, 1998; Ho et al., 1999). Nevertheless, there are large regions around the world 
where no local antivenom is available. These include Central Asia, the Middle East, northern Africa 
and Southeast Asia, and also Europe. This has led several researchers to investigate the possibility of 
using antivenoms from other regions or countries to treat latrodectism.  
 
2.2.6. Antivenom cross-reactivity with other Latrodectus venoms 
It has been noted that species-specific antivenoms, such as red-back spider antivenom, are capable of 
treating envenomation from more than one kind of widow spider. Indeed clinical observations of 
antivenom use around the world and in vivo studies in mice suggest that it may be possible to use 
antivenom raised to the venom of related widow spiders from other continents to treat widow and 
related theridiid spider envenomation (Daly et al., 2001; Graudins et al., 2001; Graudins et al., 2002a). 
These observations suggest that all widow spider antivenoms may be capable of reversing clinical 
envenomation by any other Latrodectus spp. worldwide. This is supported by the observation that L. 
hasselti antivenom can neutralise the toxicity of α-LTx derived from L. tredecimguttatus venom 
(Graudins et al., 2001). This is the main neurotoxin thought to be present in all medically important 
Latrodectus spp. and possibly other theridiid spider venoms (see section 2.3.2). In particular, the low 
incidence of side-effects noted with trypsin digested red-back spider antivenom make this possible 
candidate as a ‘universal’ antivenom (Daly et al., 2001; Graudins et al., 2001). 
 
2.3. Cupboard spiders: genus Steatoda 
2.3.1. Taxonomy and distribution 
Australian researchers have recently focused on the ‘cupboard, ‘brown house’, or ‘false widow’ 
spider (Fig. 2B), descriptive terms used to encompass various species of Steatoda (Araneae: 
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Araneomorphae: Theridiidae). This is a group of comb-footed spiders related to widow spiders. Indeed 
they are often mistaken for widow spiders given their similar size and appearance. They are found 
worldwide and are endemic to most continents including Australia (Fig. 3B).  
 
2.3.2. Steatodism 
In general, bites from Steatoda spp. result in minor local symptoms not requiring any specific 
intervention. In Australia, however, two species, S. grossa and S. capensis, have been implicated in a 
small number of cases of systemic envenomation in humans, also called ‘steatodism’ (South et al., 
1998; Winkel et al., 2000; Graudins et al., 2002a; Isbister and Gray, 2003a). Indeed the most number of 
reported envenomations appear to be from Australia (Isbister and Gray, 2003a). The envenomation 
syndrome observed in more severe cases is similar to that of latrodectism except that it is typically less 
acute and there is an absence of local and regional diaphoresis (Isbister and Gray, 2003a). Indeed, it has 
recently been speculated that a number of cases of latrodectism where the spider was not identified may 
in fact be severe cases of steatodism (Isbister and Gray, 2003a). These clinical findings add further 
support to in vitro observations of an α-LTx-like effect by Steatoda spp. venoms in the isolated chick 
biventer cervicis nerve-muscle preparation (Graudins et al., 2002a). It is therefore not surprising that 
red-back spider antivenom has been successfully administered in several cases of systemic steatodism 
in Australia with resolution of all features of envenomation (South et al., 1998; Winkel et al., 2000; 
Graudins et al., 2002a; Isbister and Gray, 2003a). 
 
2.3.3. Characterisation of Steatoda venoms 
To date there has only been limited attempts to isolate the active neurotoxin from Steatoda spp. 
venoms given its apparent labile nature following reversed-phase HPLC separation of venom (Graudins 
et al., 2002a). However, S. grossa and S. capensis venoms show similar abilities to cause transmitter 
release in a variety of isolated preparations (Korszniak and Story, 1994; Graudins et al., 2002a); A. 
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Graudins and G.M. Nicholson, unpublished data). In addition, S. grossa and S. capensis venoms are 
immunogenically similar to Latrodectus venoms in western blots using red-back antivenom They also 
appear chromatographically similar using size exclusion followed by anion exchange chromatography 
(Graudins et al., 2002a; A. Graudins and G.M. Nicholson, unpublished data). This supports the clinical 
observation that red-back antivenom is efficacious in the treatment of steatodism and provides further 
evidence to suggest that Steatoda venoms contain an α-LTx-like neurotoxin.  
 
2.4. Grey house spiders: genus Achaearaneae 
In Australia, the only other spider from the family Theridiidae of any medical importance is the 
grey house spider Achaearaneae trepidariorum, an introduced but widely distributed cosmopolitan 
species. Like Steatoda spp., it is similar in shape and appearance to red-back spiders, but the abdomen 
is smaller and it is dark brown or grey in colour, lacking the characteristic red markings on the dorsal or 
ventral surfaces of Latrodectus spp. It may also have variably shaped chevrons on its dorsal surface and 
the legs often are marked with rings. Bites from these spiders have been reported to cause similar 
symptoms of persistent pain as bites from red-back and cupboard spiders. However, in the five reported 
envenomations no systemic effects were noted (Isbister and Gray, 2003b). To date, no investigation of 
the venom of this spider has been undertaken. 
 
2.5 Australian funnel-web spiders: genera Atrax and Hadronyche 
2.5.1. Taxonomy and distribution 
Australian funnel-web spider venom arguably represents the most toxic spider venom known to affect 
humans. This is based on clinical reports and lethal dose studies in animals (Wiener, 1957; Gray and 
Sutherland, 1978).  
Funnel-web spiders are a diverse group of large aggressive, nocturnal spiders (Araneae: 
Mygalomorphae: Hexathelidae: Atracinae) that are classified into two genera, Atrax and Hadronyche, 
 G.M. Nicholson et al. 16 
comprised of at least 40 species, based on morphological and electrophoretic data (Fig. 2C) (Gray, 
1988). Australian funnel-web spiders, not to be confused with the unrelated American funnel-web 
spider (Agelenopsis aperta), are found primarily along the eastern seaboard of Australia from 
southeastern Queensland to Tasmania and in a small pocket in South Australia (Fig. 3C). The Atracinae 
sub-family, containing the genera Atrax and Hadronyche, is continually undergoing taxonomic 
revisions as descriptions and distributions continual evolve. This is due to the untiring efforts of Mike 
Gray (Australian Museum, Sydney) and Robert Raven (Queensland Museum, Brisbane).  
 
2.5.2. Clinical features of envenomation 
When significant systemic envenomation occurs a unique syndrome develops which can cause death 
within 15 minutes. Between 1927 and the introduction of an antivenom for clinical use in 1980 
fourteen deaths have been reported in the medical literature (Sutherland, 1980). All deaths were caused 
by bites from the Sydney funnel-web spider A. robustus, and in all cases where sex could be 
determined, it was found to be the male of the species (Fig. 2C). This is most likely due to the 
proximity of this spider to the populated areas of the Sydney basin than an indication of differences in 
potency between species of funnel-web given that nine other Atrax and Hadronyche spp. contain 
neurotoxins active on mammals in vitro (Graudins et al., 2002c). Moreover, other species of 
funnel-web spider from varied locations in NSW and Queensland have caused serious systemic illness 
in humans. They include male H. versuta (Blue Mountains funnel-web), H. formidabilis (Northern tree 
dwelling funnel-web), H. cerberea (Southern tree dwelling funnel-web) and H. infensa (Toowoomba 
funnel-web) (Dieckmann et al., 1989; Harrington et al., 1999; Miller et al., 2000). Despite all fatalities 
being associated with the bite of male A. robustus, this sex difference in venom toxicity is not apparent 
in most other Atrax and Hadronyche spp. venoms studied to date (Graudins et al., 2002c). 
Despite having a deadly reputation, bites from this spider are an uncommon phenomenon being 
around 1% of all spider bites (Isbister and Gray, 2002). Indeed only between 5-10 severe 
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envenomations requiring antivenom are believed to occur in Australia each year (White et al., 1995). In 
addition, there is clear evidence that these spiders do not release venom or deliver ineffective ‘dry’ 
bites in most cases, with typically less than 10-25% of bites leading to severe envenomation requiring 
antivenom treatment (Harrington et al., 1999; Isbister and Gray, 2002; Isbister and Gray, 2004). 
Despite of the availability of an effective antivenom, the severity and rapidity of systemic 
envenomation dictate that bites from this spider should be considered as potentially life-threatening.  
 The envenomation syndromes observed following bites by different species of funnel-web 
spiders are identical (Dieckmann et al., 1989; Harrington et al., 1999; Miller et al., 2000). In support of 
this clinical evidence, the authors have also determined that venoms from ten Atrax and Hadronyche 
spp. cause identical effects on neuromuscular transmission in the chick biventer cervicis preparation 
(Graudins et al., 2002c). Clinical features of envenomation in primates involve initial local features 
including muscle fasciculation, sweating, and piloerection. The bite is initially very painful and 
systemic envenomation may develop extremely rapidly and has been reported as quickly as 10 minutes 
following a bite (White et al., 1995; Sutherland and Tibballs, 2001a). Early symptoms of systemic 
envenomation include perioral tingling, tongue and facial muscle fasciculation, nausea, vomiting, 
profuse sweating, salivation, lachrymation, and dyspnoea (for a summary of several clinical cases see 
Sutherland and Tibballs, 2001a). Patients may rapidly develop confusion, agitation, and coma 
associated with marked hypertension, metabolic acidosis, raised intracranial pressure, mydriasis, 
generalised muscle fasciculation, and non-cardiogenic pulmonary oedema (Torda et al., 1980). 
Children may deteriorate rapidly and death may result in 1 to 2 hours if left untreated (Sutherland and 
Tibballs, 2001a). In adults, untreated envenomation may result in marked hypotension refractory to 
fluids and inotropic agents, profound coma, and continuing, persisting muscle fasciculation. Death 
results from progressive, irreversible hypotension, or possibly raised intracranial pressure resulting 
from cerebral oedema (Torda et al., 1980). These symptoms suggest involvement of both the somatic 
and autonomic nervous systems.  
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2.5.3. Funnel-web spider antivenom  
In view of the life-threatening envenomation syndrome that may result from the bite of funnel-web 
spiders, attempts were made to develop an antivenom. Initial work by Wiener to hyperimmunise horses 
and rabbits failed to produce neutralising antibodies (Wiener, 1963). This may have been due to a 
number of factors including: (a) the use of female venom which contains very low quantities of the 
toxin responsible for neurotoxicity; (b) the active neurotoxin binds strongly to a variety of substrates 
reducing effective doses; and (c) only low levels of antibodies are obtained, even after prolonged 
immunization, and require concentration by affinity chromatography. Eventually a purified rabbit IgG 
antivenom raised to the venom of the male A. robustus was developed by Dr Struan Sutherland in 
1980, then at the Commonwealth Serum Laboratories in Melbourne. Rabbits were immunised with 
venom and the IgG fraction of their serum was separated by affinity chromatography (Sutherland, 
1980). This antivenom was released for clinical evaluation in December 1980 and was freely available 
from 1984; it represents the only example of the use of immunochemically pure rabbit IgG to treat 
human envenomation. The antivenom has also been reported to be effective in reversing envenomation 
from other species of funnel-web spider including H. formidabilis, H. infensa, H. species 14, H. 
cerberea and H. versuta (Hartman and Sutherland, 1984; Dieckmann et al., 1989; Harrington et al., 
1999; Miller et al., 2000). More recently, the authors have shown that funnel-web spider antivenom can 
neutralise the toxicity of a number of other Hadronyche and Atrax spp. venoms from both male and 
female spiders in vitro (Graudins et al., 2002c). 
Since 1980 there have been over 40 cases of funnel-web spider envenomation treated 
successfully with funnel-web spider antivenom (White et al., 1995). Antivenom therapy has markedly 
shortened the course of envenomation and resulted in reduced hospital stays as well as reduced the 
morbidity and mortality from funnel-web spider envenomation (Sutherland and Tibballs, 2001a). 
Antivenom-treated patients are commonly discharged from hospital within 1 to 3 days of antivenom 
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treatment. Prior to antivenom availability the average length of hospital stays for severe, non-fatal cases 
of envenomation was 14 days (Torda et al., 1980). Nevertheless, funnel-web antivenom is not used 
frequently and only a handful of cases per year require immunotherapy. The Australian public also has 
Struan Sutherland to thank for another major advancement in the first aid treatment of funnel-web 
spider envenomation – the pressure-immobilisation method. This technique, originally developed by 
Sutherland for the treatment of snake bite (Sutherland et al., 1979), is based on using crêpe bandaging 
and splinting of the affected limb to produce local pressure and immobilisation. This limits neurotoxin 
or venom movement, known to occur through the lymphatics (Barnes and Trueta, 1941). This first aid 
method not only delays the onset of systemic envenomation but may also allow some local destruction 
or inactivation of the venom (Sutherland, 1980). 
 
2.5.4. Natural inhibitors of funnel-web spider venom 
Kellaway was the first to study the venom of the funnel-web spider (Kellaway, 1934). He noted 
the apparent lack of toxicity when mice or guinea-pigs were forcibly bitten by A. robustus. The 
specificity of funnel-web spider venom for toxicity in primates is now well recognised with a wide 
range of non-primates only developing symptoms if massive doses of venom are administered, or if the 
venom is injected intracerebrally (Wallace and Sticka, 1955; Wiener, 1957; 1959; 1963; Duncan et al., 
1980; Tibballs et al., 1987; Little et al., 1998a; Sutherland and Tibballs, 2001a). Fortunately workers at 
the Commonwealth Serum laboratories identified in the early 1970s that 2- or 3-day-old mice appear to 
be susceptible to the venom. This greatly assisted the in vivo testing of the antivenoms rather than 
having to use primates. The apparent resistance of non-primates to funnel-web venom is thought to be 
due to the presence of IgG, and possibly cross-linked IgG and IgM, inactivating factors in their plasma 
which bind to the toxins responsible for the envenomation syndrome or may simply involve a 
non-specific reaction due to the highly basic nature of the toxins (Sheumack et al., 1991).  
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2.5.5. δ-Atracotoxins: isolation and 3D structure 
Early investigations of A. robustus venom noted that it was particularly stable under acid 
conditions or after boiling for up to one hour (Wiener, 1961a) but it was later found that the toxin 
responsible for neurotoxicity bound strongly to a variety of substrates including acrylamide gel, silica 
and glass, hampering isolation (Gray and Sutherland, 1978). This explained some of the earlier 
difficulties with loss of toxicity (Kellaway, 1934; Wiener, 1963). Later studies isolated various crude 
components of A. robustus venom including a 15-25 kDa component ‘atraxotoxin’ (Sutherland, 1973) 
and a 9.8 kDa component ‘atraxin’ (Gregson and Spence, 1983) both of which produced syndromes in 
monkeys that were indistinguishable from that following injection of whole venom (Mylecharane et al., 
1984). 
The definitive isolation of the active neurotoxin was achieved by Merlin Howden’s group, then 
at Macquarie University, Sydney. Using various purification techniques, such as ion-exchange and 
reverse-phase HPLC, the lethal neurotoxin named ‘robustoxin’ was extracted from the venom of male 
A. robustus. Early attempts at sequence determination gave conflicting and incorrect results (Gregson 
and Spence, 1983; Sheumack et al., 1984). The advent of more reliable analysis methods resulted in a 
proposed amino acid sequence of 42 residues (4.8 kDa) containing eight cysteines (Sheumack et al., 
1985).  
Due to the large number of different toxins now isolated from the venom of Atrax and 
Hadronyche spiders, peptide toxins were renamed atracotoxins (ACTX) given that all Australian 
funnel-web spiders, regardless of genus, belong to the subfamily Atracinae. The same nomenclature, 
based on that proposed previously for naming individual toxins (Fletcher et al., 1997b), will be used 
throughout this review: (Greek symbol indicating the target/mode of action, if known)-(ACTX)-(genus 
and species initials)(Arabic numeral indicating order of discovery in case of toxins with identical 
activity)(lower case alphabetic character indicating homologue). An in-depth review of the structure-
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function of δ-atracotoxins has recently been published (Nicholson et al., 2004) nevertheless, for 
completeness, a brief discussion of the structure, target and mode of action of these toxins is presented.  
Similar peptides to δ-ACTX-Ar1a (formerly robustoxin) have subsequently been found in the 
venom of other Australian funnel-web spiders including δ-ACTX-Hv1a (formerly versutoxin) and 
δ-ACTX-Hv1b from H. versuta (Brown et al., 1988; Szeto et al., 2000a) and δ-ACTX-Hs20.1a from 
Hadronyche sp. 20 (Nicholson et al., 2004) (Fig. 4A). Both δ-ACTX-Ar1a and δ-ACTX-Hv1a produce 
an envenomation syndrome in anaesthetised monkeys indistinguishable from that seen in humans 
suggesting that they are responsible for the physiological effects seen with crude venom (Phillips et al., 
1987; Mylecharane et al., 1989; Sheumack et al., 1991). A single primate-specific variant of δ-ACTX-1 
is the major active component of most Australian funnel-web spider venoms, but some species produce 
multiple δ-ACTX-1 homologues (Sheumack et al., 1985; Szeto et al., 2000a). Further screening of A. 
robustus, H. valida, H. infensa, and H. versuta venom gland cDNA libraries has also revealed the 
presence of 12 novel δ-ACTX-like mature toxins, some with single residue changes while others have 
greater variation in peptide sequence (D. Wilson and P.F. Alewood, personal communication; B. Sollod 
and G.F. King, personal communication). 
Figure 4 here 
All known δ-ACTX are tightly folded 42-residue peptides with no significant sequence 
homology with any presently known neurotoxins (Sheumack et al., 1985; Brown et al., 1988; Szeto et 
al., 2000a). The cysteine framework of δ-ACTX is unusual in bioactive peptides due to the occurrence 
of three contiguous cysteines (Cys14,15,16) and disulfide-bridged cysteine residues at both the N- and 
C-termini (Fig. 4A). However a number of spider and marine cone snail toxins have been isolated with 
a similar cysteine triplet (Ramilo et al., 1992; Corzo et al., 2003; Zeng et al., 2003). The three-
dimensional solution structures of δ-ACTX-Hv1a (Fletcher et al., 1997a) and δ-ACTX-Ar1a (Pallaghy 
et al., 1997) have been determined using NMR spectroscopy (Fig. 5A-B). Interestingly, the β sheet 
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region of the δ-ACTX-1 family of toxins contain a ‘disulfide-pseudoknot’ (Fig. 5G) which places them 
in a class of toxins and inhibitory polypeptides with an ‘inhibitor cystine-knot’ (ICK) motif (Pallaghy 
et al., 1994; Norton and Pallaghy, 1998). Within this class however, the biological activities of ICK 
toxins are quite diverse (Norton and Pallaghy, 1998) and this provided few clues to predict the target 
site of δ-ACTX from their three-dimensional fold and highlight that different biological functions are 
often grafted onto the same or similar structural scaffolds . 
 
2.5.6. δ-Atracotoxins: target site and mode of action 
Electrophysiological and neurochemical studies by Graham Nicholson’s group at the University 
of Technology, Sydney have identified the target and mode of action of the δ-ACTXs. These 
neurotoxins induce spontaneous repetitive firing accompanied by plateau potentials (Grolleau et al., 
2001; Alewood et al., 2003). This results in prolonged terminal action potentials in efferent nerve fibres 
and consequent excessive transmitter release at both autonomic and somatic nerve terminals leading to 
the symptoms seen during the envenomation syndrome. Using whole-cell patch-clamping, δ-ACTXs 
were shown by Nicholson and others to produce a slowing of tetrodotoxin (TTX)-sensitive voltage-
gated sodium channel (VGSC) inactivation. In addition, the toxins caused a modest hyperpolarising 
shift in the voltage-dependence of activation (Nicholson et al., 1994; Nicholson et al., 1998; Szeto et 
al., 2000a). The above actions of δ-ACTXs indicate that they inhibit conversion of the VGSC from the 
open to the inactivated state, resulting in sodium current remaining at membrane potentials where 
inactivation is normally complete. Interestingly, these actions are very similar, but not identical, to the 
mechanism of action of scorpion α-toxins and sea anemone toxins (Strichartz and Wang, 1986; Hanck 
and Sheets, 1995) which bind to neurotoxin receptor site 3 on the VGSC (for reviews on VGSC 
neurotoxin receptor sites see (Cestèle and Catterall, 2000). Subsequent studies by Nicholson’s group 
revealed that δ-ACTXs completely inhibit the binding scorpion α-toxins to neurotoxin receptor site-3 
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on rat brain VGSC (Little et al., 1998a; Little et al., 1998b). In collaboration with Dalia Gordon (then at 
CEA-Saclay, France) they found that binding of δ-ACTXs to VGSC, using 125I-δ-ACTX-Hv1a, 
revealed a decrease in binding affinity to site 3 under depolarising conditions similar to scorpion 
α−-toxins (Gilles et al., 2002). In light of the subtle variations in action and binding properties (Little et 
al., 1998b; Nicholson et al., 1998), it suggests that δ-ACTX interact at a non-identical yet overlapping 
site to that of scorpion α−-toxins at site 3. 
Of interest has been the finding that δ-ACTXs are, in addition to being toxic to mammals, also 
insecticidal showing similar signs of delayed contractile paralysis as the anti-insect scorpion α-toxin 
LqhαIT (Eitan et al., 1990; Little et al., 1998a). In collaboration with Marcel Pelhate and Bruno Lapied 
(Université d’Angers, France), Nicholson showed that δ-ACTX-Hv1a modified the action potential of 
isolated giant axon and dorsal unpaired median neurons of the cockroach Periplaneta americana by 
prolonging the repolarisation phase, causing the development of spontaneous plateau action potentials. 
Under voltage-clamp conditions, these alterations in neuronal excitability were found to be due to a 
slowing of VGSC inactivation and a shift in the voltage-dependence of activation towards more 
negative potentials (Grolleau et al., 2001). These actions are very similar to LqhαIT (Eitan et al., 1990) 
and almost identical to that observed in mammalian preparations (Nicholson et al., 1994; Nicholson et 
al., 1998). Further radioligand binding experiments revealed that δ-ACTXs compete with the insect-
selective toxin LqhαIT, a well defined ligand of insect VGSC receptor site 3, on cockroach neuronal 
membranes (Little et al., 1998a; Gilles et al., 2001). Nevertheless, δ-ACTX-Hv1a exhibits a 
surprisingly low binding affinity to locust VGSC (Gilles et al., 2001). Thus, unlike scorpion toxins, 
which are only capable of differentiating between mammalian and insects VGSC, δ-ACTXs 
differentiate between different insect VGSC. Therefore it is clear that the δ-ACTXs are extremely 
potent and define a new class of toxins affecting both insect and mammalian VGSC. 
 G.M. Nicholson et al. 24 
Interestingly the three-dimensional fold of these toxins is different from the previously 
determined structures of the scorpion α-toxin Aah-II and the sea anemone toxin anthopleurin-A despite 
similar actions on VGSC inactivation (Fletcher et al., 1997a). However, the three groups of toxins 
share a number of topologically related anionic and cationic residues. This allowed the construction of 
a possible molecular model, based on electrostatic complementarity, to explain how all of these toxins 
might interact with a patch of charged residues within the S3-S4 loop of domain IV of the VGSC. More 
recently, structural comparison of δ-ACTX-Hv1a to various scorpion toxins suggests a similar putative 
bioactive surface but a narrower overall shape. This may simplify its association with both cockroach 
and mammalian receptor site 3 and facilitate its association with different conformations of receptor 
site-3, correlated with closed/active and slow-inactivated channel states (Gilles et al., 2001).  
Recently, Szeto et al. (Szeto et al., 2000a) also isolated and sequenced another novel spider 
δ-toxin; δ-ACTX-Hv1b (Fig. 4A). This toxin also slows VGSC inactivation but lacks insecticidal 
activity an action that may be due to the lack of charged residues at positions 4 and 5 of δ-ACTX-Hv1b 
(Szeto et al., 2000a). This knowledge allows the possibility of manipulating key residues, thus enabling 
the construction of a δ-ACTX that is insect-selective lacking vertebrate activity. The product would be 
highly desirable as a bioinsecticide given the potential high selectivity and potency.  
 
2.5.7. ω- and κ-Atracotoxins: insecticidal neurotoxins 
Recent years have seen a noticeable increase in the search for insect-specific spider toxins that 
may be useful either as insecticide leads, or in defining novel insecticide targets (for reviews see (King 
et al., 2002; Maggio et al., 2004; Tedford et al., 2004). This is of particular importance following the 
emergence of insecticide-resistant insect populations (Feyereisen, 1995) and the heightened awareness 
of environmental and human health risks of classical agrochemicals (Betarbet et al., 2000).  
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The original reports of an insecticidal action of funnel-web spider venom dates back to the mid 
1950s when Saul Wiener reported that Drosophila were susceptible to A. robustus venom (Drummond 
and Wiener, 1956; Wiener, 1957). Later work by Ron Atkinson (University of Southern Queensland, 
Toowoomba) reported the insecticidal potency of A. robustus, H. versuta and H. infensa crude venoms 
and various venom fractions extracted by reversed-phase HPLC (Atkinson et al., 1996). When injected 
into the larvae of an economically important agricultural pest the cotton bollworm (Helicoverpa 
armigera), these partially purified toxins induced essentially identical excitatory syndromes involving 
continuous writhing followed by death (Atkinson et al., 1996). 
Several families of insecticidal neurotoxins have now been isolated, their three-dimensional 
structures and insectophore (target binding residues) determined. This research has been led by Glenn 
King’s group, formerly at the University of Sydney but now at the University of Connecticut Health 
Center, USA. These toxins include two structurally distinct families of ω-ACTX, which selectively 
inhibit insect VGCCs (Fletcher et al., 1997b; Wang et al., 1999; Wang et al., 2001), and the insecticidal 
κ-ACTX (Wang et al., 2000) which recently has been shown to inhibit insect target voltage-gated 
potassium channels (Gunning et al., 2003b) (for a review of insecticidal ACTXs see King et al., 2002; 
Maggio et al., 2004; Tedford et al., 2004). 
The ω-ACTX-1 group are a family of neurotoxins of 36-37 residues, containing six conserved 
cysteine residues involved in three disulfide bonds (Figures 4B). ω-ACTX-Hv1a selectively acts on the 
insect voltage-gated calcium channel (VGCC) causing rapid inhibition of whole-cell calcium currents 
in cockroach neurons (Fletcher et al., 1997b). The three-dimensional structure and insectophore has 
also been determined for ω-ACTX-Hv1a using alanine-scanning mutagenesis (Tedford et al., 2001) 
(Figures 5C and 5H). 
A second family of ω-atracotoxins that specifically block insect VGCCs has also been reported 
(Wang et al., 2001). The ω-ACTX-2 family contains 41-45 residues with six conserved cysteines that 
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form three disulfide bonds and are unrelated to the ω-ACTX-1 family (Figures 4C). The three-
dimensional structure reveals a highly ordered disulfide-rich N-terminal core domain but a structurally 
disordered C-terminal domain (Fig. 5D). Interestingly, ω-ACTX-Hv2a shows certain structural, 
chemical and functional similarities to ω-agatoxin IVA from the unrelated American funnel-web spider 
Agelenopsis aperta (Kim et al., 1995; Wang et al., 2001). Due to difficulties with expression of ω-
ACTX-Hv2a the insectophore is currently unknown. 
Finally, another family of three homologous insect-selective neurotoxins has been isolated from 
the venom of H. versuta (Wang et al., 2000). These peptides were originally named the ‘Janus-faced’ 
atracotoxins (J-ACTXs) after the two-faced Roman god Janus, due to their asymmetric distribution of 
charged residues (Wang et al., 2000). Each have 36-37 residues and contain eight conserved cysteine 
residues with four disulfide bonds (Fig. 4D). The three-dimensional structural investigation reveals an 
extremely rare vicinal disulfide bridge, which is critical for insecticidal activity (Figures 5E and 5I). 
However, they show no homology with ω- or δ-ACTXs (Wang et al., 2000). Unlike the ω-ACTXs the 
J-ACTXs are excitatory neurotoxins (Fletcher et al., 1997b; Wang et al., 1999). The molecular target of 
this family of toxins has recently been identified by Nicholson and King as an insect potassium channel 
(Gunning et al., 2003b) and as such the family has been renamed κ-ACTX to denote this action. Part of 
the insectophore (Maggio and King, 2002) also contains the classical Lys-Phe/Tyr diad of other 
classical BKCa channel blockers (Dauplais et al., 1997) although it would appear that the Arg8 residue 
in κ-ACTX family is too bulky to fit in the pore of the potassium channel (Fig. 5I).  
Therefore these peptides represent a unique family of insecticidal neurotoxins that would be 
suitable for future development as novel bioinsecticides. Incorporation of the gene encoding these 
toxins into insect-selective baculoviruses should increase virus efficacy and reduce time-to-kill such as 
has been trialled with other toxins (for a recent review see Inceoglu et al., 2001). Although recently this 
approach has become less favoured due to the growing public concern of the use of genetically 
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modified organisms and tight legislation controlling their release, particularly in Europe. Nevertheless 
mapping of their insectophore using site-directed mutagenesis will provide important information for 
the rational design of non-peptide mimetics suitable as foliar sprays. This approach has received 
encouraging validation following successful creation of a non-peptide analogue that topologically 
mimics the key residues of ω-conotoxin MVIIA, a N-type calcium channel blocker (Menzler et al., 
2000). The identification of a range of insect ion channels as previously unvalidated insecticide targets 
yet again emphasises the necessity for unbiased approaches, not based on the structure or target of 
existing chemical pesticides, in the discovery of new insecticides. This should hopefully prevent the 
rapid development of insecticide-resistance already prevalent in many agriculturally and medically 
important arthropods. Their phyla-specificity also means that there is reduced likelihood of the human 
or vertebrate toxicity associated with current chemical pesticides. 
 
2.5.7. Other atracotoxins 
During the search for anti-mammalian and anti-insect toxins a number of other peptides have 
been isolated from the venom of funnel-web spiders. The first of these was ACTX-Hvf17 a 68-residue 
non-toxic peptide with five disulfide bonds isolated from the venom of the Australian funnel-web 
spider Hadronyche versuta. It does not function like classical neurotoxins in modulating ion channel 
function as evidenced by its lack of insecticidal activity and its inability to affect skeletal muscle 
contractility (Szeto et al., 2000b). The polypeptide shows partial sequence homology with a variety of 
peptides targeting EG-VEGF receptors involved in amongst many activities, gastrointestinal smooth 
muscle activation (Fig. 4E). These polypeptides include mamba intestinal toxin 1 (MIT1) from the 
black mamba Dendroaspis p. polylepis (Boisbouvier et al., 1998), Bv8 a small peptide isolated from 
skin secretions of the toad Bombina variegata (Mollay et al., 1999), the prokineticin family of proteins 
(also known as endocrine gland-derived, vascular endothelial growth factor or EG-VEGF) (Li et al., 
2001), and the C-terminal region of the embryonic head inducer Dickkopf-1 family of proteins (Glinka 
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et al., 1998). It also shares some homology with porcine colipase but lacks colipase activity (Szeto et 
al., 2000b). The sequence homology between these prokineticin-like proteins led King and Nicholson 
to propose that ACTX-Hvf17 also adopts the pharmacological feature of prokineticin to stimulate 
gastrointestinal motility and facilitate the digestive process after the spider has killed its prey. However, 
we have recently shown that ACTX-Hvf17 does not stimulate smooth muscle contractility on rat 
stomach fundus or guinea-pig ileum seen with prokineticins and MIT1, nor is the peptide active on 
other smooth muscle preparations including guinea-pig trachea or rat vas deferens (S. Wen, W.C. 
Hodgson and G.M. Nicholson, in preparation). Therefore it appears that ACTX-Hvf17 may adopt an 
ancestral protein fold, refered to as a disulfide-directed β-hairpin, but that mutation in the primary 
sequence results in the loss of activity on gastrointestinal smooth muscle.  
More recently Paul Alewood’s and David Craik’s groups at the University of Queensland, 
Brisbane have determined the primary sequence and three-dimensional structure of ACTX-Hi:OB4219, 
a novel peptide toxin isolated from the Australian funnel-web spider Hadronyche infensa Orchid Beach 
(Rosengren et al., 2002). ACTX-Hi:OB4219 contains 38 amino acids with four disulfide bonds (Fig. 
4F) forming an ICK motif, a fold consistent with all other ACTX whose structure has been determined 
to date. Interestingly this toxin possesses two equally populated conformers in solution arising from 
cis/trans isomerisation of the bond preceding Pro30 (Fig. 5F). Despite showing a similar fold to the 
insect sodium channel toxins µ-Aga-I and µ-Aga-IV (from the unrelated American funnel-web 
Agelenopsis aperta) and an ICK motif consistent with an ion channel target, ACTX-Hi:OB4219 shows 
only limited primary sequence homology to the µ-agatoxins and curtatoxins (Fig. 4F) and the target of 
this toxin is yet to be determined. 
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2.6. Australian mouse spiders: genus Missulena 
2.6.1. Taxonomy and distribution 
Australian mouse spiders (Araneae: Mygalomorphae: Actinopodidae) belonging to the genus 
Missulena are primitive hunting spiders. There are eleven species of mouse spider, which are found in 
all states of Australia except Tasmania. The main species that have been studied so far are the eastern 
mouse spider, Missulena bradleyi (Fig. 2D) that is distributed along the eastern coastal and highland 
regions of Australia including the Sydney basin (Fig. 3D) and the northern mouse spider (M. pruinosa) 
found in Darwin and the Northern Territory (Fig. 3D). 
 
2.6.2. Clinical manifestations of mouse spider envenomation 
Bites by mouse spiders are very rare, or at least rarely reported, despite their distribution all over the 
Australian mainland and the habit of males roaming about during daylight hours. However, the general 
public is not familiar with mouse spiders and often mistakes them for funnel-web spiders or less 
venomous spiders. The most severe systemic envenomation was in 1985, in Gatton near Toowoomba in 
Queensland where a 19-month-old girl was bitten on the finger by an identified male M. bradleyi 
spider. Within 30 minutes the girl began vomiting and lost consciousness. Ensuing symptoms were 
muscle fasciculation, dyspnoea, hypertension, heavy perspiration and tachycardia. These symptoms 
resemble those caused by the envenomation of a funnel-web spider and her condition fully recovered 
after administration of Sydney funnel-web antivenom (Rendle Short, 1985). Additional reports of 
envenomation have also been documented from various other species of mouse spider. Of the 40 
confirmed envenomations where the spider could be identified only the case reported above was 
associated with severe neurotoxic envenoming (Isbister, 2004). Nevertheless, six bites by M. bradleyi 
caused local neurotoxic effects such as paraesthesia and diaphoresis and several were associated with 
minor systemic effects such as headache, nausea and vomiting (Isbister, 2004). This highlights the 
potentially serious, but rare, nature of systemic mouse spider envenomation. 
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2.6.3. Characterisation of Missulena venoms 
To date there has been very little pharmacological characterisation of the venom of mouse 
spiders. Crude venom of the red-headed mouse spider M. occatoria appears to be potentially as potent 
as the Sydney funnel-web spider A. robustus. Missulena occatoria venom was found to have a median 
lethal dose (LD50) of 0.2 µg (s.c.) in newborn mice, compared with 2.1 µg for male A. robustus venom 
(Sutherland, 1979). 
The only other study to be carried out on mouse spider venom was performed by Rash et al. 
(Rash et al., 2000a). This group showed that male, but not female, M. bradleyi venom produced potent 
effects on transmitter release on a variety of isolated smooth and skeletal neuromuscular preparations 
(Rash et al., 2000a). Whole-cell patch clamp experiments using rat dorsal root ganglion neurons 
revealed that male M. bradleyi venom causes a slowing of VGSC inactivation with a modest 
hyperpolarising shift in the voltage-dependence of activation (Rash et al., 2000a). This action is 
analogous to that of δ-ACTXs (Nicholson et al., 1994; Nicholson et al., 1998; Szeto et al., 2000a) and it 
therefore appeared that male M. bradleyi venom may contain a δ-ACTX-like toxin. This was further 
supported by the clinical finding that Sydney funnel-web antivenom neutralises the toxicity caused by 
the envenomation of the male M. bradleyi spider both clinically (Rendle Short, 1985) and in vitro 
(Rash et al., 2000a). 
 
2.6.4. δ-Missulenatoxins 
Following reverse phase HPLC separation of male M. bradleyi venom, the authors isolated a 
42-residue peptide with unusual N- and C-terminal cysteines and a cysteine triplet (Gunning et al., 
2003a). This toxin was highly homologous to the δ-ACTX-1 family of toxins from Australian 
funnel-web spiders including conservation of all eight cysteine residues (Fig. 4A) and was therefore 
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named δ-missulenatoxin-Mb1a (δ-MSTX-Mb1a) in accordance with the nomenclature system for 
funnel-web spider toxins. Subsequent whole-cell patch-clamp electrophysiology revealed that 
δ-MSTX-Mb1a modulated VGSC gating and kinetics in a similar fashion to the δ-ACTX-1 family. 
δ-MSTX-Mb1a therefore provides evidence of a highly conserved spider δ-toxin from a 
phylogenetically distinct spider family that has not undergone significant modification. 
 
2.7. Necrotising arachnidism in Australia: fact or fiction? 
In recent years there has been considerable controversy concerning the potential of some spiders 
to cause necrotic cutaneous lesions. With overseas spiders, such as recluse spiders (Loxosceles spp.), 
this is well documented (Schenone et al., 1989; Bascur et al., 1992; Futrell, 1992). Conversely in 
Australia, while many spiders including the white-tailed spider (Lampona spp.), black house spider 
(Badumna spp.), wolf spiders (Lycosidae) and sac spiders (Cheiracanthium spp.) have been implicated, 
there is no evidence that spiders cause necrotic arachnidism. The spiders most implicated since the 
early 1980s are the white-tailed spiders (Lampona cylindrata and L. murina). A recent prospective 
study by Geoff Isbister of 130 identified white-tailed spider bites showed no cases of necrotic skin 
lesions (Isbister and Gray, 2003b) and in cases of suspected necrotic ulcers a diagnosis other than 
spider bite was made following appropriate investigation of bacterial, fungal and mycobacterial 
cultures and skin biopsy for histopathology (Isbister and Whyte, 2004). This is supported by other 
clinical (White et al., 1989; Isbister, 2001; Isbister and Gray, 2002) and in vitro studies of the venom 
(Rash et al., 2000b; Young and Pincus, 2001). For a more complete review of Australian spiders 
implicated in necrotising arachnidism readers are directed to a recent review (Isbister and White, 2004). 
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3. Australian scorpion toxinology 
3.1. Taxonomy and distribution 
Scorpions are an ancient group of arthropods, with approximately 1400 species recognised 
worldwide today, organised into between nine and fourteen families, depending on the classification 
system followed. There are around 40 named species of Australian scorpions distributed within four 
families (Fig. 1B), although it is estimated that 150-200 species may exist (E. Volschenk, unpublished 
data). Unlike their overseas counterparts, scorpions in Australia are rarely encountered and have 
received little attention (Southcott, 1976). Species from three families are relevant to this review; 
Lychas marmoreus (family Buthidae), Cercophonius squama (family Bothriuridae) and Urodacus 
hoplurus (family Urodacidae). 
Scorpions of the Buthidae family are highly successful errant opportunists, and are found all 
across the globe (Lucas and Meier, 1995).  They are the dominant scorpions of Africa, America and 
Asia.  They include many of the significantly toxic genera such as Leiurus, Androctonus, Buthus, 
Centruroides and Tityus.  Buthids reached Australia from South East Asia, and have colonised the 
entire continent except the most southern islands and have given rise to several endemic species and 
genera (Koch, 1977). Of these Lychas marmoreus is medically relevant and the most widespread 
(Figures 2E and 3E).  
The only medically important member of the Bothriuridae is Cercophonius squama (Figures 2F 
and 3F). This scorpion is widespread across the cooler, moister south and east of the continent (Koch, 
1977). While they occupy a similar niche to the buthids, they tend to be more cryptic than buthids, and 
are thus encountered less often.   
The Urodacidae (close relatives of the Scorpionidae) are an endemic family of scorpions found 
across the continent except on the south-eastern seaboard. The genus Urodacus is the only genus of the 
family Urodacidae and comprises some 20 described species (Koch, 1977; Volschenk et al., 2000). Due 
to their burrowing nature they are well suited to drier conditions than the errant scorpions, and are 
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consequently the dominant scorpion family over much of the continent. A closely-studied 
representative example is U. hoplurus, (Fig. 2G) which is widespread in western and central Australia 
(Koch, 1977) (Fig. 3G). 
 
3.2. Clinical toxicity and laboratory studies 
The medical importance of these Australian scorpions is minor in comparison with the large 
number of deaths associated with their overseas counterparts in Mexico, the Middle East and North 
Africa (Dehesa-Davila et al., 1995). The only Australian scorpions implicated in serious 
envenomations are the buthid Lychas marmoreus and the bothriurid Cercophonius squama (Sutherland 
and Tibballs, 2001b; Isbister et al., 2003b). Both of these scorpions are errant in nature, without 
permanent burrows, and have slender pedipalps and chelicerae. They consequently rely heavily on their 
venom for predation and for defense.  The tiny L. marmoreus appears to have the most dangerous 
venom to humans (Isbister et al., 2003b). Initial pain and swelling at the sting site is followed by 
paraesthesia and hyperalgesia lasting for several (1-8) hours, after which numbness and tingling may 
persist for several days (<15% of cases).  Nausea, vomiting, malaise and occasionally tachycardia are 
seen in 10% of cases.  One well-documented death of an infant girl in West Australia in 1929 was 
probably due to this scorpion (Southcott, 1976). The second species, C. squama, was probably 
responsible for the death of a baby girl in Tasmania in the early 1950’s, but no documentation exists.  
Several stings due to this species have occurred also on the mainland too, and the clinical picture 
includes severe local inflammation and intense pain, accompanied by vomiting and oedema of the 
whole limb (Sutherland and Tibballs, 2001b). This is borne out by preliminary animal toxicity studies 
(Wilson and Nicholson, 2003).  
The Urodacidae have proportionally much larger pedipalps to catch and crush their prey, and 
correspondingly less potent anti-mammalian venom (Wilson and Nicholson, 2003).  Whilst 
envenomation from these scorpions is not known to present any risk of fatality, the brief but intense 
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localised pain of their stings is well known anecdotally, especially to field biologists (E. Volschenk, 
personal communication; (Isbister et al., 2003b). More interest has centred on the potential use of 
insecticidal toxins from urodacid scorpions, as they produce larger amounts of venom than scorpions of 
the other Australian families, and the potential for novel classes of compound following their extended 
period of relative isolation (Wilson and Nicholson, 2003). Recently work by two of the authors has 
identified a novel insect-selective VGSC blocker from the venom of U. hoplurus (Wilson et al., 2003).  
 
4. Australian tick toxinology 
4.1 Taxonomy and distribution 
Ticks belong to the order Acarina, which also contains mites. Tick toxicosis, a type of paralysis 
resulting from envenomation following a tick bite, occurs in different regions of the world. Over 60 of 
the ~820 tick species (belonging to 10 different genera) having been implicated in paralysis or other 
signs of toxicosis. However, the extent of tick toxicosis is not known. Worldwide, ticks are of far 
greater importance as vectors of various diseases, such as Q Fever, tick typhus and Lyme disease, not 
covered in this review as they do not represent a form of envenomation.  
In Australia, tick toxicosis has only been associated with the hard ticks (ticks with a fully 
sclerotised dorsal plate) of the family Ixodidae (Fig. 1C) that are found along the eastern coastal strip 
from North Queensland to Victoria (Fig. 3H). This limited distribution is the result of a dependence on 
environmental conditions such as high humidity and the presence of the natural hosts including various 
species of bandicoots (Perameles nasuta and Isoodon macrourus) and the koala (Phascolarctos 
cinereus). In Australia, the main tick species responsible for tick toxicosis is Ixodes holocyclus (Fig. 
2H), however there have been several reports that two other tick species, I. cornuatus and I. hirsti are 
also capable of producing paralysis (Tibballs and Cooper, 1986; Stone and Aylward, 1987). These ticks 
are very similar in appearance to I. holocyclus but are less common and have a restricted range. 
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4.2. Tick toxicosis 
There have been some 20 fatalities recorded due to bites from ticks in Australia between 1900 
and 1945 (Sutherland and Tibballs, 2001c). Importantly this figure is more than the deaths from either 
red-back or funnel-web spider bites, both of which are considered to be more medically important. In 
addition, ticks cause countless numbers of deaths in companion and feral animals particularly dogs, 
which seem especially vulnerable.  
Toxicosis caused by I. holocyclus is best characterised in dogs and consists of initial weakness 
of the hind limbs followed by a rapidly ascending flaccid paralysis. The paresis then increases and 
extends to the forelimbs and respiratory muscles (Albiston, 1968). Similar symptoms occur in humans, 
although they may suffer from more serious facial nerve involvement. Other symptoms include loss of 
appetite and voice, incoordination, excessive vomiting or regurgitation, respiratory distress and often, 
in the absence of timely antitoxin treatment, death (Stone et al., 1989). This progressive neuromuscular 
paralysis was thought to result in death due to respiratory failure but it now appears that cardiac 
dysfunction may contribute (Campbell, 2002). 
Initially, tick paralysis was thought to be the result of the transmission of a micro-organism 
although attempts to identify a pathogen were unsuccessful (Dodd, 1921; Ferguson, 1924). Ian Clunies 
Ross first demonstrated that the toxic effects on mice and dogs could be produced with an extract of 
tick salivary glands (Ross, 1926) but it was not until 1983 that the presence of a toxic activity was 
conclusively demonstrated in tick saliva (Stone et al., 1983a). In this study, female I. holocyclus, 
partially engorged (4 days) on mice, were attached to an artificial membrane and allowed to feed on a 
culture medium supplemented with fetal calf serum. The feeding material was collected, concentrated 
and shown to produce paralysis in mice identical to that observed with salivary gland extracts. 
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4.3. Isolation of salivary neurotoxins 
A toxic fraction of I. holocyclus was first isolated by Kaire at the Commonwealth Serum 
Laboratories, Melbourne and shown to produce paralysis in dogs consistent with tick toxicosis (Kaire, 
1966). This activity could be neutralised by the anti-tick serum that had been commercially produced 
by the controlled engorgement of female ticks on dogs. The toxic component was shown to be resistant 
to digestion with proteases (pepsin, trypsin and papain), heating at 75 °C for 15 min, and moderate pH 
(3-9) changes. 
Over a 10 year period from the late 70’s to late 80’s, Dr Bernard Stone and colleagues at the 
CSIRO Long Pocket Laboratories in Queensland carried out research on I. holocyclus which 
characterised the feeding processes (Stone et al., 1979), the structure and development of the salivary 
glands (Stone et al., 1989), immunity to artificial infestation (Stone et al., 1983b) and toxoids (Stone 
and Neish, 1984; Stone et al., 1986), identified allergens (Gauci et al., 1988), developed improved 
antitoxin assays (Stone et al., 1982a) and made significant progress in the purification of the paralysing 
toxin(s) (Stone et al., 1982b; Stone and Aylward, 1987; Stone et al., 1989). Two subsequent studies 
(Davey et al., 1989; Thurn and Broady, 1992) confirmed the ability to produce a highly toxic fraction 
from engorged female ticks where the toxic activity was associated with proteins with masses variously 
reported between 40-80 kDa. Similar size toxins were being reported around the same time from other 
tick species; Rhipicephalus e. evertsi (Viljoen et al., 1986) and Argas (Persicargas) walkerae (Viljoen 
et al., 1990). 
A breakthrough in the identification of the I. holocyclus neurotoxin was made in an experiment 
where proteins in the partially purified active fraction from engorged salivary glands were radio-
iodinated, bound to rat brain synaptosomes (pinched-off nerve terminals), separated by SDS-PAGE and 
visualised by autoradiography (Thurn and Broady, 1992). A single band was seen with Mr of 5 kDa. 
Subsequent separation by HPLC techniques identified three neurotoxins (holocyclotoxins; HT-1, HT-2 
and HT-3). These neurotoxins have masses comparable with those from other arachnids such as spiders 
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(3-11 kDa) and scorpions (5-8 kDa). Sufficient HT-1 was purified to obtain a partial amino acid 
sequence (Thurn, 1994) and this data was used in PCR experiments to isolate the gene encoding the 
neurotoxin (Masina and Broady, 1999). The gene sequence encodes a mature polypeptide with a 
calculated mass of 5.9 kDa and a calculated basic pI of 8.86. The neurotoxin gene and the leader 
sequence show strong homology to scorpion neurotoxin genes. Only a single cDNA sequence was 
obtained. More recently the gene has been isolated from genomic DNA and shown to have the same 
sequence and no introns (M. Padula and K.W. Broady, unpublished data). These observations suggest 
that HT-1, HT-2 and HT-3 are derived from a single gene and undergo post-translational modification 
or partial degradation within the saliva of the tick. 
Recombinant forms of HT-1 have been produced in several expression systems (Masina, 1999; 
Chung, 2001) and shown to be highly immunogenic. However, the antibodies have only demonstrated 
low levels of protection against tick toxicosis and reactivity to the native toxin. It is interesting to note 
that cardiotoxic activity recently reported in I. holocyclus (Campbell, 2002) may further complicate the 
issue of controlling tick toxicosis by vaccination. 
 
4.4. Mechanism of action of salivary neurotoxins 
Although a purified native or active recombinant neurotoxin from I. holocyclus has not been 
available for functional characterisation, two studies by Ian Spence (formerly at the Roche Marine 
Pharmacology Institute, Sydney but now at the University of Sydney) reported electrophysiological 
experiments on dogs and mice paralysed by I. holocyclus (Cooper and Spence, 1976; Spence, 1979). 
These studies confirmed the observations of ascending hind limb paralysis and indicated that the 
neurotoxin(s) acted peripherally at the neuromuscular junction by inhibiting the release of 
acetylcholine, possibly by inhibiting calcium influx. It was also observed that the effects of the 
neurotoxin(s) were temperature-dependent with less activity at temperatures below 37 °C. This unusual 
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temperature effect was also observed in the synaptosome binding experiments (Thurn and Broady, 
1992) where the radiolabelled neurotoxin(s) did not bind at 0 °C.  
 
4.5. Antivenom 
From the time of the earliest observations (Ross, 1935; Oxer, 1948) that dogs can become 
immune to tick paralysis and that the passive transfer of serum from immune dogs can arrest tick 
paralysis in both animals and children (Pearn, 1983), a small veterinary antiserum industry has been 
operating. This polyclonal hyperimmune antiserum forms the basis of treatment for tick paralysis. It is 
relatively expensive and only effective if administered early before full flaccid paralysis develops. It is 
envisaged that the production of active recombinant neurotoxin HT-1 will be a major step towards the 
development of a protective vaccine against paralysis caused by I. holocyclus. 
 
5. Conclusions, future directions and further applications 
Despite a recent upsurge of interest in arachnid venoms by various research groups there still 
remains many challenges for Australian toxinologists. Clinically, there exists the unresolved issues of 
the effectiveness of intravenous vs. intramuscular antivenom usage, the apparent overdiagnosis of 
‘necrotic arachnidism’, and in many cases the unknown rate and severity of envenomation in several 
Australian species of spiders and scorpions. Also many arachnid neurotoxins still remain 
uncharacterised, both biochemically and pharmacologically. This is particularly evident with scorpion 
and tick neurotoxins. While the development of antivenoms and first aid treatment for spider 
envenomation is well advanced in Australia, thanks to the labors of clinicians such as the late Struan 
Sutherland, little is known of antivenom cross-reactivity and efficacy in treating related and unrelated 
spider envenomation. Is a universal antivenom for theridiid spider envenomation possible? Moreover a 
tick vaccine still eludes us. 
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Given the extensive number of uninvestigated arachnid venoms, there exists a vast treasure of 
untapped and potentially useful peptides and proteins. Estimates of the peptide diversity of spider 
venoms indicates that they have a much larger pharmacological inventory than the conopeptides from 
the venoms of cone snails, currently receiving much attention as sources of potential pharmaceutics. 
Many of these arachnid toxins are already being investigated as molecular tools in the neurosciences to 
define the subtype and structure-function of mammalian and/or insect ion channels. In particular, the 
phyla-specificity of insect-selective atracotoxins has provided a range of previously unvalidated insect 
targets. Thus spider toxins hold great promise as potential leads in the development of novel 
biopesticides and target-based insecticide screens.  
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Fig. 1. Partial taxonomy of medically important Australian arachnids. (A) Relationship of the orders 
Aranaea, Acarina and Scorpiones within the Class Arachnida. (B) Taxonomy of the order Scorpiones, 
with particular reference to the families represented in Australia (modified from (Prendini, 2000). (C) 
Taxonomy of the order Acarina (modified from (Barker and Murrell, 2002). 
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Fig. 2. Medically important Australian arachnids. (A) Female red-back spider (Latrodectus hasselti). 
(B) Female cupboard spider (Steatoda grossa). (C) Male Sydney funnel-web spider (Atrax robustus). 
(D) Male eastern mouse spider (Missulena bradleyi). (E) Female little marbled scorpion (Lychas 
marmoreus). (F) Female Cercophonius squama. (G) Female Urodacus hoplurus. (H) Partially 
engorged female Australian paralysis tick (Ixodes holocyclus).  
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Fig. 3. Distribution maps of medically important Australian arachnids. (A) Red-back spider 
(Latrodectus hasselti). (B) Cupboard spiders (Steatoda spp.). (C) Funnel-web spiders (Atrax and 
Hadronyche spp.). (D) Eastern mouse (Missulena bradleyi) and northern mouse spiders (M. pruinosa). 
(E) Little marbled scorpion (Lychas marmoreus) (F) Cercophonius squama. (G) Urodacus hoplurus. 
(H) Australian paralysis ticks (Ixodes spp.). 
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Fig. 4. Primary structures of atracotoxins. (A-F) Amino acid sequences showing identical residues 
boxed in grey and conservatively substituted residues in grey text. Where determined, disulfide-
bonding patterns for the cysteine residues are indicated above the sequences while key functional 
residues as determined by alanine-scanning mutagenesis are indicated by arrowheads below the 
sequences. Panels show (A) δ-ACTX-1, (B) ω-ACTX-1, (C) ω-ACTX-2 and (D) κ-ACTX-1 families. 
Included in (A) is the sequence of δ-MSTX-Mb1a from the eastern mouse spider Missulena bradleyi. 
(E) Alignment of ACTX-Hvf17 with MIT1, Bv8 and selected members of the prokineticin family of 
proteins. (F) Alignment of ACTX-Hi:OB4219 with µ-agatoxins and curtatoxins. Sequences were 
prepared using ALSCRIPT. 
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Fig. 5. Schematic views of atracotoxin solution structures. (A) δ-ACTX-Hv1a (PDB file 1VTX), (B) 
δ-ACTX-Ar1a (PDB file 1QDP), (C) ω-ACTX-Hv1a (PDB file 1AXH), (D) ω-ACTX-Hv2a (PDB file 
1G9P) and (E) κ-ACTX-Hv1c (PDB file 1DLO) showing the location of β-strands (cyan arrows) and 
310-helix (green and yellow). (F) Schematic view of ACTX-Hi:OB4219 showing the cis (yellow; PDB 
file 1KQH) and trans (green; PDB file 1KQI) conformations of the toxin. Cis/trans isomerism occurs at 
the bond preceding Pro30 (blue tubes). In all structures disulfides bridges form an inhibitor cystine-knot 
 G.M. Nicholson et al. 61 
(ICK) motif and are shown as red tubes. Note: The solution structure for ω-ACTX-Hv2a (D) represents 
an ensemble 10 structures showing the disordered C-terminal tail. (G) View of the ICK motif of 
δ-ACTX-Hv1a. The Cys14-Cys31 disulfide (yellow backbone with red disulfides) pierces a 14-residue 
loop formed by the Cys1-Cys15 and Cys8-Cys20 disulfides (red) and the intervening sections of the 
backbone (green) to create a pseudo-knot. (H-I) Molecular surface representations indicating key 
residues involved in the insectophore of ω-ACTX-Hv1a (H) and κ-ACTX-Hv1c (I). Models were 
prepared using MOLMOL and PyMOL.  
